Dyslipidaemia in HIV-infected patients: Association with adherence to potent antiretroviral therapy

International Journal of STD and AIDS

Volumn 12, Issue 7, 2001, Pages 463-468

  Vergis, E N ^a   Paterson, D L ^a   Wagener, M M ^a   Swindells, S ^b   Singh, N ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Adherence; Dyslipidaemia; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; INDINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG POTENCY; DRUG USE; DYSLIPIDEMIA; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RNA, VIRAL; TRIGLYCERIDES; VIRAL LOAD;

EID: 0034934844     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462011923507     Document Type: Article

References (44)

1. Declining morbidity and mortality among patients with advance human immunodeficiency virus infection: HIV Outpatient Study Investigators
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less: AIDS Clinical Trials Group 320 Study Team
3. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
4. Hyperglycemia associated with protease inhibitors in HIV infected patients
5. Protease inhibitor-associated hyperglycemia
6. New-onset diabetes mellitus associated with the use of protease inhibitors
7. Atypical accumulations of fatty tissue
8. Visceral abdominal-fat accumulation associated with use of indinavir
9. 'Buffalo hump' in men with HIV-1 infection
10. Indinavir-associated lipodystrophy
11. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
12. Marked hyperlipidaemia on ritonavir therapy
13. Evidence of unique metabolic effects of protease inhibitors
14. Antiretroviral safety and durability of ritonavir (RIT)-saquinavir (SQV) in protease inhibitor-naive patients in year two follow-up
15. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy
16. Preliminary results of a compliance study within CPCRA 007 Combination Nucleoside Study (NuCombo). For the Terry Beirn Community Programs for Clinical Research on AIDS
17. Adherence to the antiretroviral treatment in asymptomatic HIV-infected patients
18. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing adherence
19. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease
20. Virological failure and adherence to antiretroviral therapy in HIV-infected patients
21. Does lowering serum cholesterol levels lower coronary heart disease risk?
22. Detection and evaluation of dyslipoproteinemia
23. Patient selection for primary and secondary prevention of dyslipidaemia - Clinical practice guidelines
24. Clinical goals for cholesterol management in secondary prevention of coronary heart disease
25. The effects of antiretroviral protease inhibitors (PIs) on serum lipids and glucose in HIV-infected patients
26. Lipid abnormalities associated with use of protease inhibitor: Prevalence, clinical sequelae and treatment
27. Serum lipid changes in HIV-infected patients under combination therapy containing a protease inhibitor
28. Significant increases in serum cholesterol are seen among HIV patients taking protease inhibitors
29. Retrospective evaluation of the incidence of lipodystrophy in patients treated with nelfinavir+stavudine and lamivudine
30. DPC Study 006 investigator team
31. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors
32. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients
33. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: A cohort study
34. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
35. Studies of body composition and fat distribution in HIV-infected and control subjects
36. Localized adipose tissue hypertophy in patients receiving human immunodeficiency virus protease inhibitors
37. 'Buffalo hump' in HIV-1 infection
38. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
39. Metabolic complications of antiretroviral therapies
40. Adipose redistribution in human immunodeficiency virus-seropositive patients: Association with CD4 response
41. The assessment of refill compliance using pharmacy records: Methods, validity, and applications
42. Compliance issues in medical practice